This trial is active, not recruiting.

Condition prostate cancer
Treatment mvct
Sponsor University of Kentucky
Start date March 2013
End date April 2014
Trial size 10 participants
Trial identifier NCT01810627, 13-RAD-01


This is a non-randomized study to evaluate the utility of MVCT as a quality assurance measure in patients treated with interstitial permanent seed implants for low and intermediate risk prostate cancer. All patients will received the same standard of care treatment but will receive an additinoal CT image of the prostate.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose diagnostic
Patients will receive an additional MVCT scan at their one month follow up visit.
Patients will receive an additional MVCT scan at their one month follow up visit.

Primary Outcomes

Change in prostate volume measured in cm^3
time frame: One month post implant

Eligibility Criteria

Male participants from 50 years up to 80 years old.

Inclusion Criteria: Male 50-80 years of age Eligible for interstitial brachytherapy implants Exclusion Criteria: -

Additional Information

Official title Application of Megavoltage Imaging to Reduce Artifact Following Interstitial Seed Implants for Prostate Adenocarcinoma
Principal investigator William St. Clair, MD
Trial information was received from ClinicalTrials.gov and was last updated in March 2013.
Information provided to ClinicalTrials.gov by University of Kentucky.
Location data was received from the National Cancer Institute and was last updated in June 2016.